UTAA06

UTAA06 is a universal gamma delta T cell therapy engineered with a B7-H3 targeting chimeric antigen receptor (CAR). It is being developed for the treatment of relapsed/refractory acute myeloid leukemia and advanced malignant solid tumors. The therapy works through immunologic cytotoxicity, where modified gamma delta T cells target and attack cancer cells expressing the B7-H3 antigen (CD276). UTAA06 represents a novel approach in immunotherapy, leveraging the natural cytotoxic properties of gamma delta T cells enhanced with specific targeting capabilities through CAR technology.

Brand names

UTAA06 injectionUTAA-06 injectionUTAA 06 injection

Other names

CAR gene modified gamma delta T cell injectionCAR gene modified gdT cell injectionUTAA06-γδTgdT cell injection targeting B7-H3 chimeric antigen receptor